US Breast Cancer Therapy Market Opportunity Analysis

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Breast cancer is a type of malignancy that affects breast tissue and its incidences are increasing across the globe. It is also one of the most common cancers in American women which cause high morbidity and mortality rates. It affects both gender but most of the cases have been found to be related to females as compared to males. Data shows that the numbers of breast cancer incidences and death has remained stagnant with slight change in each year as compared to previous years. It also reflects that much change has not been observed despite use of better breast cancer therapeutics. So, it has become imperative to identify the solutions with which breast cancer could be treated effectively. Pharmaceutical companies are investing significantly in this segment to formulate effective strategy to prevent future breast cancer incidences.

Several breast cancer therapeutics have been introduced for providing higher safety and efficacy levels. These therapies belong to wide range of categories out of which some of them have achieved blockbuster status. Monoclonal antibodies (mAbs) are one of most widely used therapeutics owing to high safety, efficacy and specificity along with minimized side effects. Breast cancer market in US took a major leap when Genentech’s monoclonal antibody (mAb) Herceptin got FDA’s approval in 1998. Other big pharmaceutical companies soon followed the lead and introduced breast cancer monoclonal antibodies in US. Presently, the high cost of these medicines marketed makes it difficult for breast cancer patients to introduce them in their regular therapeutic regime. It is expected that in the near future, these companies will launch cost effective breast cancer medicines. Many pharmaceutical companies are also exploring the different areas for the development of efficient breast cancer therapeutics.

US Breast cancer market is dominated by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). The inhibition of HER2 is its basic mechanism to prevent the growth and proliferation of breast cancer in women. It was approved in 2012 by the FDA for the treatment of or late-stage metastatic HER2-positive breast cancer patients.

Various pharmaceutical companies are expected to introduce novel breast cancer medicines and technologies in future. Most of them are at different stages of clinical trials and would be introduced in coming years. However, the cost of pharmacologically superior therapeutics is quite high due to which limited breast cancer patients include them in their therapeutic regime. In future, the high cost breast cancer medicines will be replaced by affordable medicines due to advancements in technologies. Nanotechnology based breast cancer medicines are being developed whose introduction in US may take time. New molecular targets are also being investigated that would help in development of innovative medicines in coming years. These developments shows that US breast cancer market will increase as new products would be introduced. In this way, future of breast cancer therapeutics in US seems to be optimistic.

\"US Breast Cancer Therapy Market Opportunity Analysis\" Report Highlight:

US Breast Cancer Incidence & Prevalence
US Breast Cancer Therapy Market Overview
US Breast Cancer Drug Clinical Pipeline by Company & Phase
US Breast Cancer Drug Clinical Pipeline: 251 Drugs
Majority Drugs in Phase-II Trials: 73 Drugs
Marketed Breast Cancer Drugs in US: 32 Drugs
Breast Cancer Patent Analysis

1. US Breast Cancer Incidence & Prevalence

2. US Breast Cancer Therapy Market Overview

2.1 Current Market Scenario

2.2 US Breast Cancer Drug Pipeline Overview

3. US Breast Cancer Therapy Market Dynamics

3.1 Favorable Market Parameters

3.2 Commercialization Challenges

4. US Breast Cancer Therapy Market Future Prospects

5. Mechanism of Breast Cancer Drugs

6. US Breast Cancer Drug Clinical Pipeline by Company & Phase

6.1 Research

6.2 Preclinical

6.3 Clinical

6.4 Phase-0

6.5 Phase-I

6.6 Phase-I/II

6.7 Phase-II

6.8 Phase-II/III

6.9 Phase-III

6.10 Preregistration

6.11 Registered

7. Marketed Breast Cancer Drug Clinical Insight & Patent Analysis by Company in US

7.1 Albumin-Bound Paclitaxel (Abraxane®)

7.2 Anastrozole (Arimidex®)

7.3 Capecitabine (Xeloda®)

7.4 Docetaxel (Taxotere®)

7.5 Eribulin (Halaven®)

7.6 Everolimus (Afinitor®)

7.7 Exemestane (Aromasin®)

7.8 Fluoxymesterone

7.9 Fulvestrant (Faslodex®)

7.10 Gadobutrol

7.11 Gemcitabine (Gemzar®)

7.12 Goserelin (Zoladex®)

7.13 Ixabepilone (Ixempra®)

7.14 Lapatinib (Tykerb®)

7.15 Letrozole (Femara®)

7.16 Paclitaxel (Taxol®)

7.17 Palbociclib (Ibrance™)

7.18 Pertuzumab (Omnitarg™)

7.19 Pertuzumab Companion Diagnostic (HER2 FISH pharmDx)

7.20 Pertuzumab Companion Diagnostic (HercepTest)

7.21 Raloxifene (Evista®)

7.22 Tamoxifen Oral Liquid (Soltamox®)

7.23 Tc 99m Tilmanocept (Lymphoseek®)

7.24 Technetium Tc 99m Sulfur Colloid Diagnostic Injection

7.25 Temsirolimus (Fareston®)

7.26 Trastuzumab (Herceptin®)

7.27 Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)

7.28 Trastuzumab Companion Diagnostic (HER2 FISH pharmDx)

7.29 Trastuzumab Companion Diagnostic (HercepTest)

7.30 Trastuzumab Emtansine (Kadcyla®)

7.31 Vinorelbine

7.32 Vitamin B12 Fluorescent-Analogues (CobalaFluor Green™, CobalaFluor Red™)

8. Discontinued & Suspended Breast Cancer Drug in Clinical Pipeline in US

8.1 No Development Reported

8.2 Discontinued

8.3 Preregistration-Submission Withdrawal

8.4 Suspended

9. Competitive Landscape

9.1 AbbVie

9.2 Agilent Technologies

9.3 ARIAD Pharmaceuticals

9.4 AstraZeneca

9.5 Bayer

9.6 Biodesix

9.7 BioMarin Pharmaceutical

9.8 Boehringer Ingelheim

9.9 Bristol Mayer Squibb

9.10 Celgene Corporation

9.11 Dako A/S

9.12 Debiopharm

9.13 Dyax

9.14 Eisai

9.15 Eli Lily

9.16 Exelixis

9.17 GalaxoSmithKline

9.18 Incyte Corporation

9.19 Ligand Pharmaceuticals

9.20 Merck

9.21 Navidea Biopharmaceuticals

9.22 Nektar Therapeutics

9.23 Novartis

9.24 Onyx pharmaceuticals

9.25 Pfizer

9.26 Roche

9.27 Sanofi

9.28 Sun Pharmaceuticals

Figure 1-1: US -Estimated Breast Cancer Incidences, 2013-2015

Figure 1-2: US - Estimated Breast Cancer Deaths, 2013-2015

Figure 1-3: US -Estimated Incidences of Female Breast Cancer, 2013-2015

Figure 1-4: US -Estimated Female Breast Cancer Deaths, 2013-2015

Figure 1-5: US -Female Breast Cancer Incidence Compare to Others Cancers, 2015

Figure 1-6: US -Female Breast Cancer Deaths as compared to other Cancers, 2015

Figure 1-7: Diagnosis of Breast Cancer in Different Genders

Figure 1-8: US -Estimated Male Breast Cancer New Cases, 2013-2015

Figure 1-9: US -Estimate Male Breast Cancer Deaths, 2013-2015

Figure 2-1: US - Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015

Figure 2-2: US -Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015

Figure 2-3: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015

Figure 2-4: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015

Figure 2-5: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015

Figure 2-6: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015

Figure 2-7: US - Suspended Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015

Figure 2-8: US -Suspended Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015

Figure 3-1: US Breast Cancer Market Drivers

Figure 3-2: US Breast Cancer Therapy Market Commercialization Challenges

Figure 5-1: Type of Breast Cancer Treatment

Figure 5-2: Type of Breast Cancer Surgery

Figure 5-3: Mechanism of Trastuzumab

Figure 5-4: Mechanism of Docetaxel

Figure 5-5: Mechanism of Tamoxifen

Figure 9-1: AbbVie-Clinical Pipeline

Figure 9-2: ARIAD-Clinical Pipeline

Figure 9-3: Celgene Clinical Pipeline

Figure 9-4: Debiopharm-Clinical Pipeline

Figure 9-5: Eisai-Clinical Pipeline

Table 1-1: US -Estimated Number of New Cases for Female Breast Cancer by State, 2015

Table 1-2: US -Estimated Number of Deaths for Breast Cancer by State, 2015

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

US Breast Cancer Therapy Market Opportunity Analysis

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected